We discovered the possibility of detecting early-stage pancreatic cancer with our unique single enzyme activity-based liquid biopsy technology.

Currently, a screening test for pancreatic cancer is under development, as well as research and development for various types of cancer and non-cancer diseases.

We support drug development by searching for enzyme activity biomarkers using technology that comprehensively evaluates enzyme activity in blood with ultra-high sensitivity at the single molecule level.

Our technology has the potential to support drug development for various purposes, such as patient stratification and drug efficacy evaluation.

Subjects: Patients (colorectal, pancreatic, esophageal cancer), healthy subjects, mice

Samples: Plasma, serum, cell lysate

1 μL of body fluid is sufficient for measurement.

Our main interest lies in oncology, neurodegenerative diseases, immunological diseases, etc. However, we are willing to meet as wide a range of needs as possible.

                   

Biomarker discovery (early diagnosis, patient stratification, drug efficacy evaluation, etc.)

Assessment of target engagement of enzyme inhibitors